COVID-19 has caused obstacles in continuing normal life almost everywhere in the world by
causing the implementation of social distancing and eventually imposing the lockdown. This …

Background The interaction between COVID-19, non-communicable diseases, and chronic
infectious diseases such as HIV and tuberculosis is unclear, particularly in low-income and …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Aims: To evaluate the efficacy and safety of hydroxychloroquine/chloroquine, with or without
azithromycin, in treating hospitalized COVID-19 patients. Materials & methods: Data from …

(1) Background: Since its discovery, COVID-19 has caused more than 256 million cases,
with a cumulative death toll of more than 5.1 million, worldwide. Early identification of …

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression …

Purpose Corticosteroids, in particular dexamethasone, are one of the primary treatment
options for critically ill COVID-19 patients. However, there are a growing number of cases …

The host response to COVID-19 pathophysiology over the first few days of infection remains
largely unclear, especially the mechanisms in the blood compartment. We report on a …

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar
concentrations by targeting the host protein eukaryotic translation elongation factor 1A …

Background: Preexisting cardiovascular disease (CVD) is perceived as a risk factor for poor
outcomes in patients with COVID-19. We sought to determine whether CVD is associated …